GenScript ProBio Funding: $240M Raised, Series C (2023)
GenScript ProBio is based in Nanjing, China. It has raised $240M in total funding. Latest round: Series C.
GenScript ProBio funding overview
GenScript ProBio is based in Nanjing, China. GenScript ProBio has raised $240M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in April 2023. The round record for GenScript ProBio runs through 2023; nothing later has been disclosed. Investors on record include Legend Capital, China Merchants Capital, New Alliance Capital, Highlight Capital, C&D no.7 Holdings, CTSII Fund. 6 distinct backers are named across the disclosed rounds.
GenScript ProBio at a glance
Total raised
$240M
Latest round
Series C
Latest round date
April 2023
Headquarters
Nanjing, China
Notable investors
Legend Capital, China Merchants Capital, New Alliance Capital, Highlight Capital, C&D no.7 Holdings, CTSII Fund
Frequently asked about GenScript ProBio funding
How much has GenScript ProBio raised?
GenScript ProBio has raised $240M in total disclosed funding across the rounds on record.
Who has invested in GenScript ProBio?
Legend Capital, China Merchants Capital, New Alliance Capital, Highlight Capital, C&D no.7 Holdings, CTSII Fund are named among the investors backing GenScript ProBio.
What was the latest GenScript ProBio funding round?
The most recent disclosed round is a Series C, announced in April 2023.
Where is GenScript ProBio based?
GenScript ProBio is based in Nanjing, China.
When did GenScript ProBio last raise?
The last disclosed GenScript ProBio round closed in April 2023 at Series C.
Every GenScript ProBio figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Nanjing at a similar stage.
